[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spinocerebellar-ataxias\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spinocerebellar-ataxias":22},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,31,57,84,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":18,"phases":4,"briefSummary":19,"conditions":20,"keywords":4,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":24,"lastUpdatePostDateStruct":25,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":28,"locationsCount":4},"100518772","expanded-access-protocol-of-troriluzole-in-patients-with-spinocerebellar-ataxia-sca-100518772",false,"NCT06034886","Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)","Intermediate-Size Patient Population Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)","Key Inclusion Criteria:\n\n* Patient has a confirmed diagnosis of Spinocerebellar Ataxia (SCA), defined as either clinical evidence supporting diagnosis OR confirmed genotypic diagnosis.\n* Adequate hepatic function.\n\nKey Exclusion Criteria:\n\n* Patient is known to have acute or chronic liver disease that is clinically significant in the judgement of the Physician.\n* Patient has a history of a clinically significant medical condition that would interfere with the patients ability to comply with the expanded access protocol or would place the patient at increased risk.","ALL","18 Years","EXPANDED_ACCESS","The purpose of this expanded access protocol is to provide access to the investigational drug troriluzole in patients with spinocerebellar ataxia (SCA).",[21,22],"SCA","Spinocerebellar Ataxias","AVAILABLE","2026-01-08",{"date":26,"type":27},"2026-01-09","ACTUAL",{"name":29,"class":30},"Biohaven Pharmaceuticals, Inc.","INDUSTRY",{"id":32,"slug":33,"hasResults":11,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":4,"eligibilityCriteria":37,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":38,"enrollmentInfo":39,"targetDuration":4,"studyType":42,"phases":43,"briefSummary":45,"conditions":46,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":51,"completionDateStruct":52,"leadSponsor":54,"locationsCount":4},"100585152","efficacy-of-cerebellar-transcranial-magnetic-stimulation-to-treat-hereditary-spinocerebellar-ataxias-100585152","NCT06898645","Efficacy of Cerebellar Transcranial Magnetic Stimulation to Treat Hereditary Spinocerebellar Ataxias","Clinical Study on the Effecacy of Transcranial Magnetic Stimulation of Intermittent Theta Pulse Stimulation(iTBS) Navigated Targeting the Cerebellum in the Treatment of Hereditary Spinocerebellar Ataxia","Inclusion Criteria:\n\n* SCA1\u002F2\u002F3 patients confirmed by genetic testing\n* aged 18-65 years\n* presence of ataxia with a score3-20 on the Scale for the Assessment and Rating of Ataxia (SARA) and a score\\\u003C60 on the International Cooperative Ataxia Rating Scale (ICARS)\n* Signed informed consent by patients or their family members\n\nExclusion Criteria:\n\n* Patients with serious medical conditions (such as kidney failure, liver disease) and uncontrolled high blood pressure or diabetes\n* Patients with severe cognitive and behavioral disorders or mental illness\n* Pregnant and lactating patients; Use other ongoing clinical medications, except for neuroprotective agents such as coenzyme Q10, butylphthalein, or cyticholine; If patients are taking valproate, riluzole and other drugs but they and their guardians have a strong desire for treatment, they can be evaluated again after washout.\n* History of stroke, encephalitis and epilepsy\n* Pacemakers, electronic devices and intracranial metal objects.","65 Years",{"count":40,"type":41},80,"ESTIMATED","INTERVENTIONAL",[44],"NA","Spinocerebellar ataxia (SCA) is a type of autosomal dominant ataxia and there is currently no effective treatment. The goal of this clinical trial is to learn the efficacy of navigated iTBS (Intermittent theta-burst stimulation) targeting the cerebellum to treat hereditary spinocerebellar ataxias in adults and explore the role and neural plasticity mechanisms. It will also learn about the safety of cerebellar transcranial magnetic stimulation. The main questions it aims to answer are:\n\n1. Does navigated iTBS targeting the cerebellum improve the symptoms and clinical scale score of ataxias?\n2. Safety evaluation measures included treatment-related dizziness, head and neck pain, tinnitus, hearing loss, and epilepsy. Adverse reactions were reported by both subjects and investigators.\n\nParticipants will:\n\n1. Navigated iTBS targeting the cerebellum or sham stimulation every day for 7 day,\n2. Assessments were made at baseline, within 24 hours after the end of treatment, after 12 weeks, and after 24 weeks of telephone follow-up.",[22],"NOT_YET_RECRUITING","2025-03-20",{"date":50,"type":27},"2025-03-27",{"date":48,"type":41},{"date":53,"type":41},"2027-12-31",{"name":55,"class":56},"Xijing Hospital","OTHER",{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":42,"phases":66,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100562215","cycling-based-priming-coordination-training-for-enhancing-ataxia-recovery-and-brain-plasticity-100562215","NCT06600269","Cycling-Based Priming Coordination Training for Enhancing Ataxia Recovery and Brain Plasticity","The Effect of Cycling Priming Coordination Training on Ataxia and Brain Plasticity","Inclusion Criteria:\n\n\\- Clinical diagnosis of SCA.\n\nExclusion Criteria:\n\n* Musculoskeletal injuries on legs\n* Osteoporosis.\n* Any peripheral or central nervous system injury or disease patients.",{"count":65,"type":41},40,[44],"Effective walking and balance require not only lower limb muscle strength but also coordinated movement. For individuals with Spinocerebellar Ataxia (SCA), rehabilitation strategies targeting coordination are essential to improving mobility and reducing the burden on caregivers. However, evidence-based rehabilitation approaches for ataxia remain limited.\n\nRecent studies suggest that improvements in motor learning are often accompanied by changes in cortical excitability. Abnormal cortical excitability in SCA patients may hinder rehabilitation efforts, yet priming strategies-such as exercise or specific stimuli-have been shown to enhance motor learning by modulating cortical excitability. Cycling exercise, in particular, has demonstrated the potential to improve coordination and influence cortical plasticity in individuals with SCA, making it a promising priming strategy for coordination training.\n\nThis clinical trial aims to:\n\n1. Investigate the priming effect and neural mechanisms of acute cycling exercise on coordination training in patients with SCA.\n2. Explore the long-term impact of priming cycling training on cortical plasticity and functional mobility in individuals with SCA.\n\nThis study seeks to provide insights into optimized rehabilitation interventions that could enhance the quality of life and independence for people with SCA.",[22],[70,71,72,73],"Transcranial Magnetic Stimulation (TMS)","Gait","Motor Control","Motor Learning","RECRUITING","2024-10-04",{"date":77,"type":27},"2024-10-08",{"date":75,"type":27},{"date":80,"type":41},"2026-08",{"name":82,"class":56},"Chang Gung University",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":42,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100546617","phase-2-stemchymal-for-polyglutamine-spinocerebellar-ataxia-100546617","NCT06397274","Stemchymal® for Polyglutamine Spinocerebellar Ataxia","A Phase II, Randomized, Double-Blind, Placebo-controlled, Single-Center Study to Evaluate the Safety and Efficacy of Stemchymal (Allogeneic Adipose-derived Mesenchymal Stem Cells) Infusion for the Treatment of PolyQ Spinocerebellar Ataxia","Inclusion Criteria:\n\n1. Subjects are with genotypically confirmed SCA3.\n2. Subjects' SARA scores are in the range of 5 to15.\n3. Subjects are between 20 and 70 years of age.\n4. Subjects who have signed informed consent.\n5. Female subjects of child-bearing potential who are capable of conception must be post-menopausal (one year or greater without menses), surgically incapable of childbearing, or practicing effective methods of birth control.\n6. Male subjects must be practicing a medically accepted form of contraception during the study period. Abstinence is an acceptable method of contraception.\n\nExclusion Criteria:\n\n1. Subjects who have been enrolled in any kind of cell therapy within six months prior to screening visit (Visit 1).\n2. Female subjects who have a positive pregnancy test result.\n3. Subjects who have had severe vital organ diseases, including but not limited to cardiac (e.g., heart failure), liver (e.g., acute hepatic failure or chronic liver cirrhosis), lung (e.g., respiratory failure) and renal (e.g., hemodialysis or peritoneal dialysis) diseases, within six months prior to screening visit (Visit 1).\n4. Subjects with immunological disorders (e.g., systemic lupus erythematosus), within six months prior to screening visit (Visit 1).\n5. Subjects with other neurological disorders (e.g., Alzheimer's disease), within six months prior to screening visit (Visit 1).\n6. Subjects who had received chemotherapy\u002Fradiotherapy within five years prior to screening visit (Visit 1).\n7. Subjects with any history of malignant tumors.\n8. Subjects with dementia or other psychiatric illnesses, including but not limited to disabling depression, bipolar disorder, schizophrenia.\n9. Subjects with a Beck Depression Inventory Second Edition (BDI-II) score of over 20 points.\n10. Subjects not suitable for this clinical trial according to investigator's judgment.","20 Years","70 Years",{"count":94,"type":41},20,[96],"PHASE2","The purpose of the clinical trial is to study the therapeutic efficacy and safety of Stemchymal® infusions for polyglutamine spinocerebellar ataxia treatment by a randomized, double-blind, placebo-controlled study design. Eligible subjects will receive Stemchymal® through intravenous infusion.",[22],"2024-04-29",{"date":101,"type":27},"2024-05-02",{"date":103,"type":41},"2025-06-01",{"date":105,"type":41},"2028-06-01",{"name":107,"class":30},"Steminent US, Inc.",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":16,"minAge":116,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":83},"100441883","biomarker-research-in-inherited-movement-disorders-100441883","NCT05034172","Biomarker Research in Inherited Movement Disorders","BIOMOV","Inclusion Criteria:\n\nCommon inclusion criteria for all participants:\n\n\\- - Affiliated with a social security system or beneficiary of such a regime\n\nGroup of patients:\n\nAny patient with inherited hyperkinetic movement disorders can be included in the study according to the following criteria:\n\nWoman or man;\n\n* Clinical diagnosis of inherited hyperkinetic movement disorders with or without a genetic diagnosis\n* With or without familial history of the disease\n* Age ≥ 7 years;\n* Signed Informed consent by the patient or both of holders of the parental authority for minors, or by the le;gal guardian for adults under guardianship\n\nGroup of at-risk individuals:\n\n* Woman or man;\n* Age ≥ 18 years old;\n* A first-degree relative of a patient with inherited hyperkinetic movement disorders\n* OR a carrier of an identified pathogenic variant or expansion in one of the pathological gene variant involved in one of these diseases;\n* Normal neurological examination; according to disease specific scales\n* Signed Informed consent by the subject or by the legal guardian for adults under guardianship\n\nGroup of healthy controls:\n\n* Woman or man;\n* Aged ≥ 18 years old;\n* Free of known neurological pathology;\n* No significant neurological symptoms;\n* Signed Informed consent by the subject\n\nCommon inclusion criteria for elective participant for skin biopsy (optional): - Age ≥10 ans\n\n* Ability to undergo a skin biopsy\n\nCommon inclusion criteria for elective participant for MRI examination (optional): - Ability to undergo a MRI.\n\nExclusion Criteria:\n\nAbsolute criteria for non-inclusion for all groups:\n\n\\- Person deprived of their liberty by judicial decision\n\nContra-indications to MRI examination\\* (optional): metallic implant, pacemaker, artificial heart valve, brain vascular malformation, aneurysm clips, exposed by metallic fragments, artificial implants, peripheral or neuronal stimulator, insulin pump, intravenous catheter, epilepsy, metallic contraceptive device, claustrophobia,\n\nContra-indication to skin biopsy (optional):\n\n* Taking anticoagulant or antiplatelet medication (see above),\n* History of hemostasis disorders,\n* Presence of hemorrhagic risk verified by a coagulation test",true,"7 Years",{"count":118,"type":41},4000,"OBSERVATIONAL","Inherited movement disorders are rare conditions, whose cumulative prevalence are in the order of 5-10\u002F100,000 inhabitants, in most cases progressive and can lead to a significant loss of autonomy after one or more decades of evolution. They include spinocerebellar ataxias and hyperkinetic disorders (dystonias, choreas, tremor, parkinsonism and myoclonus with variable combination of those, or more complex alteration of movements). The existence of the National Reference Centre (CMR) for Rare Diseases (CMR Neurogenetics, devoted to ataxias and spastic paraparesis, dystonia and rare movement disorders and CMR Huntington, devoted to Huntington Disease) has allowed a more integrated vision of these diseases. This is illustrated, in the same family, by the occurrence of different clinical expressions of spinocerebellar ataxias and hyperkinetic disorders that share the same genetic background. Conversely, different causal mutations within the same gene may have very different ages at onset and a wide range of clinical expression, and the spectrum of new phenotypes linked to a single gene is still expanding . Many ataxia and dystonia genes are involved in similar pathways. There are numerous arguments supporting a share pathogenesis including synaptic transmission and neurodevelopment .\n\nBIOMOV project aims to :\n\n1. establish the clinical spectrum and natural history of these diseases,\n2. understand the role of genetic and familial factors on the phenotype,\n3. elucidate the molecular basis of these disorders and evaluate diagnostic strategies involving molecular tools for clinical and genetic management,\n4. develop multimodal biomarkers both for physiopathological studies and for accurate measures of disease progression,\n5. develop trial ready cohorts of well characterized genetic patients,\n6. test new therapies either symptomatic or based on pathophysiological mechanisms.",[122,22,123],"Inherited Movement Disorders","Hyperkinetic Disorders","2024-04-11",{"date":126,"type":27},"2024-04-12",{"date":128,"type":27},"2021-08-25",{"date":130,"type":41},"2031-08-25",{"name":132,"class":56},"Assistance Publique - Hôpitaux de Paris"]